12:00 AM
May 14, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ISIS-APOCIIIRx: Phase II started

Isis began a 3-month, double-blind, placebo-controlled, Canadian Phase II trial to evaluate subcutaneous ISIS-APOCIIIRx in about 100 patients with...

Read the full 71 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >